B Vitamins Reduce Homocysteine, But Not Disease in Diabetic Patients
G. Douglas Andersen, DC, DACBSP, CCN
Whenever the topic of kidney disease arises in my practice, the first thought that crosses my mind is diabetes, since almost 40 percent will eventually have kidney problems.1 There is evidence of a correlation between homocysteine levels in diabetic patients and diseases of the kidneys, heart and eyes.2 To lower homocysteine, we have a powerful, proven way to do it with three members of the B vitamin family.3 Many health care professionals have reasonably concluded that lowering homocysteine lowers the risk, degree or progression of secondary problems often seen in patients with diabetes.
Homocysteine: What Is Normal?
Normal plasma homocysteine values vary widely between labs and can range from as low as 2.2 to as high as 17 micromoles per liter (abbreviated as mcmol/L or umol/L). Homocysteine increases with age and runs ~1.5 umol/L higher in males than females. There is a debate on what is optimal, and this too is affected by gender and age. In general, "optimal homocysteine" ranges run from less than 10 to under 6 umol/L.
The DIVINe Study
The Diabetic Intervention with Vitamins to Improve Nephropathy (DIVINe) study followed a screened group of diabetic patients with kidney disease for three years. Those who met the criteria had diabetic nephropathy, but their condition was not considered advanced.4 The 238 subjects who qualified were divided into two groups. One took 2,500 mcg of folic acid, 1,000 mcg of vitamin B12, and 25 mg of vitamin B6 a day. The second group took a look-alike placebo. Eighty-three percent of the patients were white male, 81 percent had type 2 (as opposed to type 1) diabetes, and their mean age was 60. Plasma homocysteine levels at baseline were 16.4 umol/L and 14.7 umol/L in the placebo and B-vitamin groups, respectively.
Results
In approximately three years of follow-up, the B-vitamin group had mean homocysteine levels decline from 14.7 umol/L to 12.5 umol/L, while those assigned to placebo had their averages increase from 16.4 umol/L to 19 umol/L. However, the B-vitamin group also had an accelerated rate of GFR decrease, more strokes and more heart attacks. [See table]
A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant, 2008;23(4):1216-23.
The chiropractic profession is under a sophisticated and relentless assault from corporate medicine, so strategically executed that most don’t even recognize it happening. The campaign is powerful, calculated, and well-funded, demonstrated by its covert tactics and the millions being invested to carry it out. Corporate medicine's endgame wants only two things from chiropractic: all our patients and all our money – and it is getting it.
Over the past two decades, more than 18 million spinal surgeries have been performed in the United States, and cervical disc replacements represent a fair share of those. Device recalls due to design flaws can place patients in difficult clinical situations, especially those who are symptomatic and reluctant to undergo revision surgery. This case highlights the role of chiropractors in managing complex postsurgical patients, particularly those with recalled spinal implants.
UnitedHealth Group, parent company of UnitedHealthcare, has announced sweeping changes to its prior-authorization (PA) requirements that will eliminate the requirement for chiropractic care and numerous other healthcare services by the end of 2026. Doctors of chiropractic, other providers and patients have long lamented prior authorization requirements because they can delay needed treatment, limit access and even cause some patients not to pursue care.
